NEXT Barcelona

Increasing access to new therapies within Spanish private health care.

About Us

The agreement between NEXT Oncology and Quirónsalud Group established a research program that provides the highest possible number of early phase clinical trials in Spain, with locations in Barcelona and Madrid. It also offers quality, safety, and specialized care to patients enrolled in the trials, while thereby ensuring top-notch scientific rigor and creating opportunities to translate research findings to routine clinical practice.

Our Team

Josep Tabernero, M.D., PhD, MSc
Medical Director
Josep Tabernero, M.D., PhD, MSc

Medical Director

Dr. Josep Tabernero, who founded the IOB Institute of Oncology in Barcelona, coordinates both units. NEXT Oncology – Barcelona is in the Hospital Quirónsalud Barcelona and headed by site coordinator Dr. Elena Garralda. The opening of the two units boosts continued research activity and creates a great opportunity to promote clinical research in Spain.

Josep Tabernero holds MD and PhD degrees from the Universitat Autònoma de Barcelona, Spain. He is currently the Head of the Medical Oncology Department at the Vall d’Hebron Barcelona Hospital Campus, and Director of the Vall d’Hebron Institute of Oncology (VHIO).

He also co-directs the VHIO´s Gastrointestinal and Endocrine Tumours Group and the Research Unit for Molecular Therapy of Cancer (UITM) and is Principal Investigator of several Phase I pharmacodynamic studies and translational projects with molecular targeted therapies, as well as phase II and III studies with novel chemotherapeutics.

Dr. Tabernero serves on the Editorial Boards of various top tier journals including Annals of Oncology, ESMO Open, Cancer Discovery and Clinical Cancer Research. He has (co) authored approximately 450 peer-reviewed papers.

Dr. Tabernero was on the Executive Board of the European Society for Medical Oncology (ESMO) having served as ESMO President 2018 – 2019. He is also member of the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and has been appointed as member of several Educational and Scientific Committees of ESMO, ASCO, AACR, AACR/NCI/EORTC, ASCO Gastrointestinal, and ESMO-GI/WCGIC meetings.

Elena Garralda, M.D.
Medical Oncologist
Elena Garralda, M.D.

Medical Oncologist

Dr. Garralda is a medical oncologist and clinical investigator who focuses her research on targeted agents, early drug development, translational research, and immunotherapies. She received her medical degree from the Universidad Autónoma de Madrid and completed her medical oncology specialization at the Hospital Universitario Madrid. Dr. Garralda also earned a Master’s degree in molecular oncology from the Centro de Estudios Biosanitarios Madrid.

Contact Us

Developing a new drug is a complex undertaking. Before a drug can be brought to market, there must be proof that it is safe, that it has an impact on the disease, and that this impact offers patients added benefits over existing treatments. Early phase clinical trials therefore allow patients to be treated with novel drugs that are potentially more effective and better tolerated.

If you are interested in participating in trials at NEXT Oncology, please contact us to learn more.

Plaza Alfons Comin 5 – 9 08023 Barcelona,
Spain

Phone: Dial 011 (+34) 934-894-332

Open Monday-Friday 8:00 AM to 5:00 PM

Call Now Button